$BMY News
Last published 1d ago
- 1d agoBMYBristol Myers Squibb Announces Evolution of Research & Development OrganizationBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Bristol Myers Squibb Announces Evolution of Research & Development Organization
- 6d agoBMYBristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific SessionsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos...
- 6d agoAAPLNVDAIBMJNJ+4U.S. Reshoring and Nearshoring: A Sustainable Economic TailwindStifel InsightsMarket Sight | Lines Investors are increasingly worried about market levels and the possibility of an artificial intelligence (AI) “bubble.” Despite the worries, however, during earnings calls and elsewhere, executives are highlighting a powerful, long-term positive theme: making more in America. What began as a reaction to pandemic-era disruptions has evolved into a structural reindustrializatio ...
- 2w agoGENBBMYNTHIAZN2027 Could Finally Be the Year Cancer Is on the Ropes!GlobeNewswireDENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
- 2w agoBMYBristol Myers Squibb Third Quarter 2026 Earnings - BRISTOL MYERS SQUIBB COEarnings Call TranscriptsWelcome to the Bristol-Myers Squibb Third Quarter 2026 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key
- 2w agoBMYBRISTOL MYERS SQUIBB CO - PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 29, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoBMYBristol Myers Squibb Reports Third Quarter Financial Results for 2026Business WireBristol Myers Squibb (NYSE:BMY) today reported third quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2026 earnings press
- 2w agoBMYIzalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyBusiness WireLate-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient
- 2w agoBNTXBMYBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyGlobeNewswirePumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression
- 3w agoBMYBristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Business WireData reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and
- 3w agoBMYPathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology PipelineBusiness WireFunding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016 Pathos AI, Inc., a clinical-stage AI and technology company advancing its own
- 3w agoTEMBMYTempus Expands Strategic Collaboration with Bristol Myers SquibbBusiness WireTempus AI, Inc. (NASDAQ:TEM, "Tempus")) today announced a multi-year agreement with Bristol Myers Squibb (NYSE:BMY, "BMS")), under which BMS will license multimodal oncology data from Tempus through 2031
- 3w agoBMYTEMPathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological ConditionsBusiness WireTempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos’s AI expertise and agentic
- 3w agoBMYIzalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 StudyBusiness WireLate-breaking results to be presented in an oral presentation at ESMO 2026 With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine treatment across breast
- 3w agoBMYBristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026Business WireLate-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer
- 1mo agoBMYBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETsBusiness WireThe study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS) Bristol Myers Squibb (NYSE:BMY) today announced positive topline results
- 1mo agoBMYBristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary EndpointBusiness WireIn the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo Admilparant demonstrated a
- 1mo agoBMYBristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...Business WireIn the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in
- 1mo agoBMYBristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care MovementBusiness WireSecond-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved CommunitiesBristol Myers Squibb (NYSE:BMY) today announced the expansion of Champions in Care, the
- 1mo agoBMYU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*Business WireCAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric population Approval based on positive results of Phase 3 SCOUT-HCM trial, building on the extensive clinical evidence for CAMZYOS in
- 1mo agoBMYBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple MyelomaBusiness WireResults presented at IMS 2026 show ZENBEXUS in combination with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41.1%
- 1mo agoBMYBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026Business WireBristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2026 on Thursday, October 29, 2026. Company executives will review financial results with the investment community during a conference call
- 1mo agoBMYBristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two YearsBusiness WireResults from the POETYK PsA-2 open-label extension demonstrated robust response rates in patients treated with Sotyktu, with clinical responses continuing to improve through year one and maintained through year
- 1mo agoBMYBristol Myers Squibb Announces DividendBusiness WireBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is
- 2mo agoQNTMNVSMRKTGTX+1Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketGlobeNewswireAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the
- 2mo agoBMYBristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...Business WireTrial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted
- 2mo agoBMYBristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026Business WireNew single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor
- 2mo agoSBFMBNTXAZNMRNA+1A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityGlobeNewswireNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is
- 3mo agoBMYU.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First RelapseBusiness WireApproval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple
- 3mo agoRNABMYAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationPR NewswireSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA
- 3mo agoBMYBristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, TexasBusiness WireNew State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS’ $40 Billion Commitment to American Innovation, Manufacturing and
- 3mo agoAZN-GBBMYAstraZeneca may buck a decade of pharma strategy to buy U.S. scaleCNBCReports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.
- 3mo agoBMYAZNAstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reportsCNBCU.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
- 3mo agoBMYBristol Myers Squibb Reports Second Quarter Financial Results for 2026Business WireBristol Myers Squibb (NYSE:BMY) today reported second quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed second quarter 2026 earnings press
- 3mo agoBMYBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIABusiness WireExpanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress
- 4mo agoBMYU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple MyelomaBusiness WireApplication based on results from SUCCESSOR-2 trial showing oral CELMoD mezigdomide in combination with carfilzomib and dexamethasone significantly improved progression-free survival vs. standard of care in this
- 4mo agoQNTMNVSMRKTGTX+1The Quest to Repair What Multiple Sclerosis Takes AwayGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure.
- 4mo agoBMYBristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026Business WireBristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call
- 4mo agoBMYBristol Myers Squibb Announces DividendBusiness WireBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is
- 5mo agoLLYBMYMRKPFE+3The space race is coming for pharma: Why drug development is heading to lower Earth orbitCNBCCompanies see a commercial opportunity in creating new ways to administer drugs to patients – in space.
- 5mo agoBMYMariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the DiseaseBusiness WireMultiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions Campaign highlights unmet needs in myeloma and new science like CELMoD
- 5mo agoBMYRCUSArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney CancerBusiness WireThis collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage,
- 5mo agoBMYIzalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell CarcinomaBusiness WireInterim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026 SystImmune and Bristol Myers Squibb's potent dual-targeted EGFRxHER3 bispecific antibody-drug
- 5mo agoBMYU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)Business WireCamzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population Application based on positive results of Phase 3 SCOUT-HCM
- 5mo agoBMYBristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin LymphomaBusiness WireFirst-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL) Bristol Myers Squibb (NYSE:BMY)
- 5mo agoBMYBNTXCARBOPLATINGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialGlobeNewswireFirst investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels
- 5mo agoBMYBristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple MyelomaBusiness WireFirst Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO® 2026 SUCCESSOR-2 data reinforce the potential of CELMoD therapies to transform outcomes for patients with RRMM Bristol Myers
- 5mo agoBMYBristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireBristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. The company will take part in a fireside chat
- 5mo agoBMYBristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation PipelineBusiness WireLate-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company's targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data
- 5mo agoBMYBristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global OperationsBusiness WireThe collaboration brings together BMS' deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and delivery of transformational medicines BMS will deploy Claude's agentic